Himalaya Nutravedics India Limited submitted its Investor Presentation for the half year ended September 30, 2026 to BSE Limited pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights (H1 FY27)

  • Revenue from Operations: ₹2,739.8 lakh (₹27.40 crore), representing 35.8% year-on-year growth compared to H1 FY26 revenue of ₹2,017.9 lakh
  • EBITDA: ₹567.2 lakh, showing 51.1% year-on-year growth from ₹375.4 lakh in H1 FY26
  • EBITDA Margin: 20.7%, an improvement of 210 basis points from 18.6% in H1 FY26
  • Profit After Tax (PAT): ₹444.1 lakh, increasing 34.6% from ₹330.0 lakh in H1 FY26
  • PAT Margin: 16.2%, slightly decreased by 14 basis points from 16.4% in H1 FY26
  • Earnings Per Share (EPS): ₹7.0, decreased from ₹8.2 in H1 FY26 (-15.7%)

Historical Financial Performance

FY26 Performance:

  • Revenue from Operations: ₹4,306.8 lakh, representing 105.1% growth over FY25
  • EBITDA: ₹810.3 lakh with EBITDA margin of 18.8%
  • PAT: ₹721.7 lakh with PAT margin of 16.8%
  • EPS: ₹11.8

FY25 Performance:

  • Revenue from Operations: ₹2,099.7 lakh, representing 45.6% growth over FY24
  • EBITDA: ₹299.0 lakh with EBITDA margin of 14.2%
  • PAT: ₹223.2 lakh with PAT margin of 10.6%

Business Model and Operational Metrics

Business Segments:

1. Own-Branded Products (Classical/Proprietary Ayurvedic & Nutraceuticals) - Contribution increased to 64.7% of total revenue in H1 FY27 from approximately 50% in FY26

2. Third-Party Contract Manufacturing - Complementary revenue stream ensuring high plant capacity utilization

Product Portfolio:

  • Ayurvedic formulations dominate revenue (98.2% of total revenue in H1 FY27)
  • Multiple dosage forms: soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils
  • Therapeutic areas: Pain Management & Musculoskeletal Care, Digestive & Gut Health, Women's Wellness & Hormonal Health, Metabolic Health, Immunity & Respiratory Wellness

Key Proprietary Products:

  • Himarex: For men's health and vitality
  • Recasage: Specialty care across renal, respiratory, and dermatological ailments
  • Nutraceutical portfolio includes Cogrite Tablets, Lythimin Tablets, and Lythmin Plus Tablets

Distribution Network:

  • Pan-India footprint across 20 states and 1 Union Territory
  • Multi-tier distribution via Super-Stockists, Stockists, and Retail Pharmacies
  • Core markets: Kerala (47.7% of H1 FY27 revenue), Gujarat, Uttar Pradesh, Telangana
  • Recently expanded to Bihar and Odisha in July 2026
  • Dedicated Carrying & Forwarding (C&F) agent arrangement covering Uttar Pradesh, Uttarakhand, Jharkhand, and Bihar

Manufacturing Capacity Utilization (H1 FY27):

  • Medicated oil utilization: 42.5%
  • Softgel Capsules utilization: 83.0%
  • Facility certifications: ISO 22000:2018, ISO 9001:2015, WHO-GMP, HACCP, HALAL, and KOSHER

Corporate Developments

  • Successfully listed on BSE SME platform in September 2026
  • Converted from private limited to public limited company
  • Recognized as a DPIIT Startup by the Government of India
  • Incorporated in June 2022, commenced commercial manufacturing operations in September 2022 from Hyderabad facility

Management Commentary

Rohit Asawa, Chairman and Managing Director, stated that H1 FY27 was "an encouraging period" marked by sustained business growth and improved operating profitability. He highlighted the growing contribution of own-branded products and expansion of distribution network. The company is focused on deploying IPO proceeds towards digital marketing and working capital requirements, with initiatives aimed at complementing the practitioner-led B2B model and building a scalable omnichannel business.

Strategic Growth Plan

1. Scaling D2C & Omni-Channel Presence: Establish proprietary D2C platform and expand presence across e-commerce marketplaces (Amazon, Flipkart) and quick commerce platforms (Blinkit, Zepto)

2. Investment in Branding & Digital Marketing: Deploy ₹750.00 lakh from IPO proceeds towards branding, performance marketing, and customer acquisition campaigns

3. Expanding Own-Branded Portfolio: Introduce new SKUs across core therapeutic segments including pain management, gut health, women's wellness, and neurological support

4. Deepening Geographic Reach: Strengthen multi-tier distribution network into tier-2 and tier-3 markets while developing export capabilities

Balance Sheet Position (H1 FY27)

  • Total Assets: ₹5,780.4 lakh
  • Shareholder's funds: ₹4,731.8 lakh (significantly increased post-IPO)
  • Cash & cash equivalents: ₹2,661.8 lakh
  • Inventories: ₹1,322.4 lakh
  • Trade receivables: ₹1,226.5 lakh
  • Short-term borrowings: ₹421.7 lakh

Cash Flow Statement (H1 FY27)

  • Net cash used in operating activities: (₹65.5) lakh
  • Net cash used in investing activities: (₹4.7) lakh
  • Net cash from financing activities: ₹2,584.4 lakh (primarily IPO proceeds)
  • Net increase in cash & cash equivalents: ₹2,517.2 lakh

Leadership Team

  • Rohit Asawa: Chairman and Managing Director (Promoter Group)
  • Abhisheak Dhoot: Independent Director
  • Krishna Kanth Sarda: Chief Financial Officer
  • Divya Asawa: Non-Executive Director (Promoter Group)
  • Ramya Inala: Independent Director
  • Pooja Biyani: Company Secretary and Compliance Officer

Investor Relations Contact

Capital Bridge Advisory Service Private Ltd serves as Investor Relations Consultant, with contacts Rishi Kothari (+91-82388 85414) and Krisha Anandpara (+91-84859 93396).